Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan
Ataru Igarashi,
Hideyuki Nomura,
Kazufumi Dohmen,
Nobuhiko Higashi,
Kazuhiro Takahashi,
Akira Kawano,
Takeaki Satoh,
Makoto Nakamuta,
Toshimasa Koyanagi,
Masaki Kato,
Shinji Shimoda,
Eiji Kajiwara
Affiliations
Ataru Igarashi
1 Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo, Tokyo, Japan
Hideyuki Nomura
4 The Center for Liver Disease, Shin-Kokura Hospital, Kitakyushu, Japan
Kazufumi Dohmen
5 Department of Internal Medicine, Chihaya Hospital, Fukuoka, Japan
Nobuhiko Higashi
6 Department of Hepatology, Steel Memorial Yawata Hospital, Kitakyushu, Japan
Kazuhiro Takahashi
7 Department of Medicine, Hamanomachi Hospital, Fukuoka, Japan
Akira Kawano
8 Department of Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
Takeaki Satoh
10 Center for Liver Disease, National Hospital Organization Kokura Medical Center, Kitakyushu, Japan
Makoto Nakamuta
11 Department of Gastroenterology, Kyushu Medical Center, National Hospital Organization, Fukuoka, Japan
Toshimasa Koyanagi
12 Department of Medicine, Fukuoka City Hospital, Fukuoka, Japan
Masaki Kato
13 Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Shinji Shimoda
14 Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
